E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Heterozygous Familial Hypercholesterolemia |
|
E.1.1.1 | Medical condition in easily understood language |
Heterozygous Familial Hypercholesterolemia |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10057079 |
E.1.2 | Term | Heterozygous familial hypercholesterolemia |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the effect of ezetimibe 10 mg/day compared to placebo on the reduction of lowdensity lipoprotein cholesterol (LDL-C) from baseline to 12 weeks of treatment in children to 10 years old with primary hypercholesterolemia (Heterozygous Familial Hypercholesterolemia [HeFH] and nonfamilial). |
|
E.2.2 | Secondary objectives of the trial |
To determine the effect of ezetimibe 10 mg/day compared to placebo on total cholesterol (TC), apolipoprotein B (Apo B), high-density lipoprotein cholesterol (HDL-C), non-HDLC, and triglycerides (TG) from baseline to 12 weeks of treatment. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
PK Sub-study: Approximately 16 subjects were asked to participate in a substudy which involves obtaining 6 additional blood samples within a 12-hour period at Visit 5. The goal of this substudy was to examine the blood levels of the study drug throughout a day. |
|
E.3 | Principal inclusion criteria |
- Each subject may be of either sex and of any race/ethnicity, and must be >=6 and <=10 years of age, with a diagnosis of primary hypercholesterolemia (heterozygous familial or nonfamilial) despite being on a lipid-lowering diet for at least 3 months with a LDL-C of >159mg/dL
- Each subject's parent/guardian must be willing to give written informed consent on his/her behalf. |
|
E.4 | Principal exclusion criteria |
Each subject must not:
- Have known hypersensitivity or any contraindication to ezetimibe.
- Have use of any investigational drugs within 30 days of study entry.
- Be a member or a family member of the personnel of the investigational or sponsor staff directly involved with this trial.
- Be a female of child-bearing potential who is pregnant, intends to become pregnant, or is nursing
- Have known congenital cardiac disorder.
- Have documented or laboratory values consistent with homozygous familial hypercholesterolemia (HoFH).
- Be known to be human immunodeficiency virus (HIV) positive. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint was the percent change from baseline in LDL-C after 12 weeks of treatment.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
LDL-C is evaluated at Day -13, -1, Day 0, Week 1-3, 4, 8, and 12. |
|
E.5.2 | Secondary end point(s) |
Key secondary efficacy endpoints were the change from baseline in TC, Apo B, non-HDLC, HDL-C and TG after 12 weeks of treatment.
Other secondary efficacy endpoints included percent change from baseline to 2, 4 and 8 in LDL-C, TC, non-HDLC, HDL-C, TG, LDL-C:HDL-C and TC: HDL-C, percent change from baseline to 12 weeks in Apo A-I and ratios of LDL-C:HDL C, TC:HDL-C, Apo B:Apo A-I, percent change from baseline to 4 and 12 weeks in serum hs-CRP, and percent change from baseline to 2, 4, 8 and 12 weeks in plasma plant sterols (sitosterol, campesterol, cholestanol) and lathosterol.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
With exception of Apo B and Apo A1, the lipid panel included in the secondary endpoint is evaluated LDL-C is evaluated at Day -13, -1, Day 0, Week 1-3, 4, 8, and 12. Apo-B and Apo A1 is assessed at Day 0 and Week 12.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
Canada |
Colombia |
Israel |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 9 |